U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039877) titled 'Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients' on June 18.
Brief Summary: Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries. With such poor 5-year overall survival rates of 10%, we need strategies that surpass the complete response rate achieved in this setting, which does not exceed 60% effectiveness with different regimens, and to eventually transfer patients to hematopoietic stem cell transplantation.
In this context, we are investigating the use of venetoclax, a BCL2 inhibitor, with the use of a cytochrom...